Hyderabad pharma maker of generic formulations & APIs sold in 150+ countries; scaling biosimilars via CuraTeQ.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 59 | 59 | 59 | 59 | 59 | 58 | 58 | 58 |
| Reserves | 16.8k | 21.9k | 24.5k | 26.8k | 29.8k | 32.6k | 35.0k | 37.8k |
| Borrowings | 5.8k | 5.3k | 2.9k | 5.3k | 6.6k | 8.3k | 7.8k | 8.1k |
| Other Liabilities | 6.1k | 6.1k | 6.2k | 7.4k | 8.2k | 8.6k | 9.7k | 12.5k |
| Total Liabilities | 28.8k | 33.4k | 33.6k | 39.5k | 44.7k | 49.5k | 52.5k | 58.5k |
| AssetsFixed Assets | 9.4k | 9.4k | 10.5k | 11.0k | 14.5k | 14.8k | 17.7k | 19.6k |
| CWIP | 2.0k | 3.1k | 3.7k | 5.4k | 3.9k | 4.9k | 3.0k | 3.0k |
| Investments | 555 | 591 | 997 | 543 | 372 | 252 | 268 | 1.1k |
| Other Assets | 16.8k | 20.4k | 18.4k | 22.5k | 26.0k | 29.5k | 31.5k | 34.8k |
| Total Assets | 28.8k | 33.4k | 33.6k | 39.5k | 44.7k | 49.5k | 52.5k | 58.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1.7k | 4.4k | 3.3k | 5.0k | 2.4k | 2.4k | 3.9k | 5.5k |
| Cash from Investing | -2.9k | -1.6k | 597 | -3.2k | -4.0k | -4.2k | -1.9k | -3.5k |
| Cash from Financing | 1.9k | -1.9k | -1.4k | -3.0k | 1.8k | 800 | 120 | -1.3k |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 114 | 3.0k | 1.5k | 2.7k | -323 | -1.1k | 1.4k | 2.5k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (20.1×) and current (25.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 22% growth and a 20× exit, ₹1533 only delivers your return if you pay ₹1,482. The price is currently baking in 23% growth.
EPS grows 22%/yr for 5 years, then fades to 6% over 2, exits at 20×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 22.0% | 73.61 |
| FY28 | 22.0% | 89.81 |
| FY29 | 22.0% | 109.57 |
| FY30 | 22.0% | 133.67 |
| FY31 | 22.0% | 163.08 |
| FY32 | 14.0% ·fade | 185.91 |
| FY33 | 6.0% ·fade | 197.07 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.